Tovaxin, radiation-attenuated, patient-specific T-cells for the therapeutic vaccination of multiple sclerosis

Current Opinion in Investigational Drugs

Volumn 9, Issue 5, 2008, Pages 534-540

  Hellings, N ^a   Stinissen, P ^a  

^a HASSELT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TOVAXIN; VACCINE;

CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; IMMUNITY; INCIDENCE; INJECTION SITE REACTION; MULTIPLE SCLEROSIS; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VACCINATION;

CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; MYELIN PROTEOLIPID PROTEIN; MYELIN-ASSOCIATED GLYCOPROTEIN; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; VACCINATION; VACCINES;

EID: 43549115915     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. 266918 Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Howell MD, Winters ST, Olee T, Powell HC, Carlo DJ, Brostoff SW SCIENCE 1989 246 4930 668-670
2. 389787 The Immune Response Corporation initiates phase I/II clinical trial for multiple sclerosis - Combination vaccine targeting aberrant T cells to be tested for ability to increase anti-inflammatory immune responses. Immune Response Corp PRESS RELEASE 2000 November 14
3. 473919 In the pipeline. Opexa Pharmaceuticals Inc COMPANY WORLD WIDE WEB SITE 2002 December 12
4. 503604 A controlled trial of natalizumab for relapsing multiple sclerosis. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O'Connor PW N ENGL J MED 2003 348 1 15-23
5. 585053 PharmaFrontiers issues $6.1 million notes. PharmaFrontiers Corp PRESS RELEASE 2005 February 14
6. 605670 PharmaFrontiers's MS drug shows promise in phase I/II trials. PharmaFrontiers Corp PRESS RELEASE 2005 June 03
7. 606430 PharmaFrontiers presented preliminary Tovaxin clinical plans at multiple sclerosis centers meeting. PharmaFrontiers Corp PRESS RELEASE 2005 June 08
8. 616294 Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Elias D, Reshef T, Birk OS, van der Zee R, Walker MD, Cohen IR PROC NATL ACAD SCI USA 1991 88 8 3088-3091
9. 624193 Pathogenesis of multiple sclerosis. Prat A, Antel J CURR OPIN NEUROL 2005 18 3 225-230
10. 631261 FDA OKs PharmaFrontiers's phase IIb MS study. PharmaFrontiers Corp PRESS RELEASE 2005 October 31
11. 772052 IRC starts European phase II study of NeuroVax for MS The Immune Response Corp PRESS RELEASE 2007 March 07
12. 780344 Opexa Therapeutics reports positive top-line data in phase I/II dose escalation trial with Tovaxin for multiple sclerosis. Opexa Therapeutics Inc PRESS RELEASE 2007 April 03
13. 780907 NCT00245622: Autologous T-cell vaccine (TCV) for multiple sclerosis. CLINICALTRIALS.GOV 2007 February 08
14. 795697 Opexa Therapeutics completes patient enrollment in phase IIb trial of Tovaxin for treatment of multiple sclerosis. Opexa Therapeutics Inc PRESS RELEASE 2007 May 17
15. 807084 Opexa Therapeutics reports positive top-line data in phase I/II extension trial with Tovaxin for multiple sclerosis. Opexa Therapeutics Inc PRESS RELEASE 2007 June 21
16. 829399 Opexa Therapeutics gives update on phase IIb trial of Tovaxin for treatment of multiple sclerosis. Opexa Therapeutics Inc PRESS RELEASE 2007 September 11
17. 847741 Opexa reports third quarter 2007 financial results. Opexa Therapeutics Inc PRESS RELEASE 2007 November 05
18. 872396 ATX-MS-1467 - Positive immunological data in multiple sclerosis - Final phase I/IIa data shows safety and tolerability, plus efficacy. Apitope Technology (Bristol) Ltd PRESS RELEASE 2008 January 30
19. 877238 CD4+ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis. Hong J, Zang YCQ, Nie H, Zhang JZ PROC NATL ACAD SCI USA 2006 103 13 5024-5029
20. 877239 T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients. Achiron A, Lavie G, Kishner I, Stern Y, Sarova-Pinhas I, Ben-Aharon T, Barak Y, Raz H, Lavie M, Barliya T, Faibel M et al CLIN IMMUNOL 2004 113 2 155-160
21. 877240 T cell vaccination in multiple sclerosis: Results of a preliminary study. Zhang JZ, Rivera VM, Tejada-Simon MV, Yang D, Hong J, Li S, Haykal H, Killian J, Zang YCQ J NEUROL 2002 249 2 212-218 • Summarizes the clinical results from a TCV trial in MS patients from the co-inventor of Tovaxin.
22. 882819 Tovaxin. Opexa Therapeutics Inc COMPANY WORLD WIDE WEB SITE 2008 March 05
23. 883048 Important safety information. Elan Corp plc; Biogen Idec Inc PRESS RELEASE 2008 February 28
24. 888295 DNA Vaccines 2008 - A Marcus Evans Forum (Part I), Bridging the gap between technology and application, London, UK, 10-11 March 2008. Ulmer JB IDDB MEETING REPORT 2008 March 10-11
25. 888795 Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA J EXP MED 2004 199 7 971-979
26. 888798 Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FoxP3 expression. Venken K, Hellings N, Hensen K, Rummens JL, Medaer R, D'hooghe MB, Dubois B, Raus J, Stinissen P J NEUROSCI RES 2006 83 8 1432-1446
27. 888800 Functional properties of myelin oligodendrocyte glycoprotein-reactive T cells in multiple sclerosis patients and controls. Van der Aa A, Hellings N, Bernard CC, Raus J, Stinissen P J NEUROIMMUNOL 2003 137 1-2 164-176
28. 888802 CD4+CD28- costimulation-independent T cells in multiple sclerosis. Markovic-Plese S, Cortese I, Wandinger KP, McFarland HF, Martin R J CLIN INVEST 2001 108 8 1185-1194
29. 888804 Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. Bielekova B, Sung MH, Kadom N, Simon R, McFarland H, Martin R J IMMUNOL 2004 172 6 3893-3904
30. 888840 Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Ben-Nun A, Wekerle H, Cohen IR NATURE 1981 292 5818 60-61 • Seminal paper that demonstrated proof-of-principle of TCV in the EAE animal model of MS.
31. 888844 Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis. Lider O, Reshef T, Beraud E, Ben-Nun A, Cohen IR SCIENCE 1988 239 4836 181-183
32. 888848 Control of experimental autoimmune encephalomyelitis by T cells responding to activated T cells. Lohse AW, Mor F, Karin N, Cohen IR SCIENCE 1989 244 4906 820-822
33. 888851 Humoral mechanisms in T cell vaccination: Induction and functional characterization of anti-lymphocytic autoantibodies. Herkel J, Brunner S, Meyer zum Buschenfelde KH, Lohse AW J AUTOIMMUN 1997 10 2 137-146
34. 888854 MHC-restricted depletion of human myelin basic proteinreactive T cells by T cell vaccination. Zhang J, Medaer R, Stinissen P, Hafler D, Raus J SCIENCE 1993 261 5127 1451-1454 • The first proof-of-principle trial of TCV in MS patients that demonstrated an induction of anti-vaccine responses paralleled with a specific and long lasting depletion of MRTC.
35. 888855 Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: Pilot trial in multiple sclerosis. Medaer R, Stinissen P, Truyen L, Raus J, Zhang J LANCET 1995 346 8978 807-808 • The first phase I clinical trial of TCV with MRTC in MS patients.
36. 888856 Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination. Hermans G, Denzer U, Lohse A, Raus J, Stinissen P J AUTOIMMUN 1999 13 2 233-246
37. 888858 Th2 immune regulation induced by T cell vaccination in patients with multiple sclerosis. Zang YC, Hong J, Tejada-Simon MV, Li S, Rivera VM, Killian JM, Zhang JZ EUR J IMMUNOL 2000 30 3 908-913
38. 890261 Immune-mediated oligodendrocyte injury in multiple sclerosis: Molecular mechanisms and therapeutic interventions. Buntinx M, Stinissen P, Steels P, Ameloot M, Raus J CRIT REV IMMUNOL 2002 22 5-6 391-424
39. 890262 Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis. Zang YC, Kozovska MM, Hong J, Li S, Mann S, Killian JM, Rivera VM, Zhang JZ EUR J IMMUNOL 1999 29 5 1692-1700
40. 890265 Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: Meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Martinelli Boneschi F, Rovaris M, Johnson KP, Miller A, Wolinsky JS, Ladkani D, Shifroni G, Comi G, Filippi M MULT SCLER 2003 9 4 349-355
41. 890266 Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial. Hartung HP, Gonsette R, König N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T LANCET 2002 360 9350 2018-2025
42. 890267 Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: Possible interventions. Stüve O, Marra CM, Cravens PD, Singh MP, Hu W, Lovett-Racke A, Monson NL, Phillips JT, Cohen Tervaert JW, Nash RA, Hartung HP et al ARCH NEUROL 2007 64 2 169-176
43. 890275 T-cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controls. Hellings N, Barée M, Verhoeven C, D'hooghe MB, Medaer R, Bernard CC, Raus J, Stinissen P J NEUROSCI RES 2001 63 3 290-302
44. 890301 Lines of T lymphocytes induce or vaccinate against autoimmune arthritis. Holoshitz J, Naparstek Y, Ben-Nun A, Cohen IR SCIENCE 1983 219 4580 56-58
45. 890302 Novel therapeutic strategies targeting the pathogenic T-cells in multiple sclerosis. Muir M, Lovett-Racke AE, Racke MK EXPERT REV CLIN IMMUNOL 2005 1 3 345-355
46. 890303 lpr T cells vaccinate against lupus in MRL/lpr mice. De Alborán IM, Gutierrez JC, Gonzalo JA, Andreu JL, Marcos MA, Kroemer G, Martínez C EUR J IMMUNOL 1992 22 4 1089-1093
47. 890337 The prevalence of multiple sclerosis in the world: An update. Rosati G NEUROL SCI 2001 22 2 117-139
48. 890358 Paving the way for autologous cell therapy for autoimmunity. Opexa Therapeutics Inc COMPANY PRESENTATION 2007 August 24
49. 892551 Identifying new immunodominant myelin peptides in relapsing remitting multiple sclerosis patients. Newsom BS, von Gynz Rekowski K, Montgomery MM, Fox E, Williams JC ANN MEET FEDERATION CLIN IMMUNOL SOCIETIES 2007 June 10
50. 892728 In vivo clonotypic regulation of human myelin basic protein-reactive T cells by T cell vaccination. Zhang J, Vandevyver C, Stinissen P, Raus J J IMMUNOL 1995 155 12 5868-5877
51. 892904 Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis. Chou YK, Bourdette DN, Offner H, Whitham R, Wang RY, Hashim GA, Vandenbark AA J NEUROIMMUNOL 1992 38 1-2 105-113
52. 892910 Reactivity pattern and cytokine profile of T cells primed by myelin peptides in multiple sclerosis and healthy individuals. Tejada-Simon MV, Hong J, Rivera VM, Zhang JZ EUR J IMMUNOL 2001 31 3 907-917
53. 893062 The gap between effect of drugs and effectiveness of treatments. Sorensen PS J NEUROL SCI 2007 259 1-2 128-132
54. 893091 Personal communication: T-cell vaccination of secondary-progressive multiple sclerosis patients. Weiner LP COMPANY COMMUNICATION 2008 February 01
55. 893092 Interferon-? treatment for multiple sclerosis. Bermel RA, Rudick RA NEUROTHERAPEUTICS 2007 4 4 633-646
56. 895812 Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M et al ARCH NEUROL 2007 64 10 1407-1415
57. 895837 The life and times of T cell vaccination. Cohen IR. In: T CELL VACCINATION AND AUTOIMMUNE DISEASE (MEDICAL INTELLIGENCE UNIT). Zhang J, Raus J (Eds), RG Landes Co, Austin, TX, USA (1995):7-17